SUDA Pharmaceuticals Ltd (ASX: SUD) is pleased to invite shareholders and interested parties to an investor webinar and Q&A hosted by CEO & Managing Director Dr Michael Baker.
The webinar will focus on today’s announcement regarding SUDA’s global licensing agreement with Imperial College London for a novel invariant Natural Killer T (iNKT) cell therapy platform. Dr Baker will be joined on the webinar by Professor Anastasios Karadimitris.
For more information, download the attached PDF.
Download this document
